Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00670553
NCT00670553
Completed
Phase 1

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Novartis Pharmaceuticals1 site in 1 country7 target enrollmentSeptember 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstate CancerHead & Neck CancerEsophageal Cancer
Interventionspanobinostat
Drugspanobinostat

Overview

Phase
Phase 1
Intervention
panobinostat
Conditions
Prostate Cancer
Sponsor
Novartis Pharmaceuticals
Enrollment
7
Locations
1
Primary Endpoint
Establish Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies.

Registry
clinicaltrials.gov
Start Date
September 2008
End Date
January 2010
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

LBH589

Intervention: panobinostat

Outcomes

Primary Outcomes

Establish Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)

Time Frame: 1 to 28 days

Secondary Outcomes

  • Safety profile of oral LBH589 when given in combination with standard Radiotherapy(min 1 month)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid TumorsSolid Tumors
NCT00556088SCRI Development Innovations, LLC40
Completed
Phase 1
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After CastrationProstate CancerProstatic Neoplasms
NCT00878436NYU Langone Health52
Completed
Phase 1
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract CancersLung CancerHead and Neck Cancer
NCT00738751H. Lee Moffitt Cancer Center and Research Institute44
Active, not recruiting
Not Applicable
A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with trastuzumab - ND
EUCTR2007-002449-19-ITOVARTIS FARMA118
Active, not recruiting
Phase 1
A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with trastuzumabHER positive metastatic breast cancerMedDRA version: 9.1 Level: LLT Classification code 10027475 Term: Metastatic breast cancer
EUCTR2007-002449-19-FRovartis Pharma Services AG